Aprea Therapeutics is a precision medicine oncology company developing small-molecule inhibitors that exploit synthetic lethality—a mechanism where mutations in two genes result in cancer cell death when targeting either alone would not be lethal. The company's pipeline focuses on inhibitors of DNA damage response pathways, including WEE1 and ATR kinases, designed to selectively kill cancer cells bearing specific genetic mutations while sparing healthy tissue, thereby reducing toxicity. Aprea generates value by advancing targeted therapies through clinical development, retaining worldwide development and commercialization rights to its candidates, partnering with contract manufacturers for production, and protecting its intellectual property through a portfolio of issued and pending patents expected to provide exclusivity into the 2030s and 2040s.